174 research outputs found
Reply to Β«Comments to the paper βDiagnosis of spondyloarthritis: Should we need new criteria?βΒ» published in the journal Β«Sovremennaya RevmatologiyaΒ»
Π ΠΏΠ΅ΡΠ²ΠΎΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Β«Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΒ» Π·Π° 2015 Π³. Π±ΡΠ»Π° ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π° ΡΡΠ°ΡΡΡ Π.Π. ΠΠ°ΠΉΠ΄ΡΠΊΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΊΡΠ»ΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΏΠ°ΡΠΊΠΈΠ½ΠΎΠΉ, Π.Π. Π Π΅Π±ΡΠΎΠ²Π° Β«ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°: Π½ΡΠΆΠ½Ρ Π»ΠΈ Π½Π°ΠΌ Π½ΠΎΠ²ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ?Β». Π ΠΎΡΠ²Π΅Ρ Π½Π° ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΡ ΡΡΠ°ΡΡΠΈ Π² ΡΡΠ΅ΡΡΠ΅ΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Π²ΡΡΠ»ΠΈ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΡΠ° Π¨.Π€. ΠΡΠ΄Π΅ΡΠ°
Diagnosis of spondyloarthritis: should we need new criteria?
A large number of classification criteria for spondyloarthritis (SpA) are simultaneously used in modern rheumatology in the almost complete absence of diagnostic criteria. This poses a number of problems, among which there are two most important ones: 1) the frequent use of classification criteria to make a diagnosis in real clinical practice; 2) the possibility of stating different nosological entities of SpA in one patient in the presence of the same clinical picture.Objective: to investigate the specific features of the diagnosis of SpA and the use of its classification criteria in clinical practice.Subjects and methods. The investigation enrolled 119 patients with the established diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), undifferentiated axial or peripheral SpA. Whether their clinical picture complied with the modified New York criteria, the European Spondyloarthropathy Study Group (ESSG) criteria, the Amor criteria, and the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial and peripheral SpA and whether the Russian version of the modified New York criteria complied with the Classification criteria of Psoriatic ARthritis (CASPAR) were determined in the patients.Results. Sixty-three patients diagnosed with AS (M45), 44 with PsA (M07.0-07.3), 8 with undifferentiated SpA (M46.9), and 4 with nonradiographic axial SpA (M46.8) were followed up by attending physicians. The latter diagnosed AS in 10 patients who met the ASAS criteria for axial PsA but not the modified New York criteria. Twenty-one patients diagnosed as having PsA simultaneously met both the CASPAR criteria and the modified New York criteria, which could establish the diagnosis of AS in these cases. Eighty-one (68.0%) out of the 119 patients met the Amor criteria; 98 (82.3%) patients, the ESSG criteria; 91 (76.5%), the ASAS criteria for axial SpA; 18 (15.1%), the ASAS criteria for peripheral SpA; 76 (63.8%), the modified New York criteria; 88 (73.9%), the Russian version of the modified New York criteria; 42 (32.3%), the CASPAR criteria. No intersection of criteria was observed in only 5 patients; 113 (94.9%) patients met β₯2 criteria; 96 (80.7%), β₯3 criteria; 81 (68.1%), β₯4 criteria; 66 (55.5%), simultaneously β₯5 criteria; and 18 (15.1%), simultaneously 6 criteria.Conclusion. Most patients with SpA meet β₯2 classification criteria, which gives the chance to state β₯2 nosological entities in the same patient. This demonstrates the elaboration of diagnostic criteria that can make a clear distinction between different forms of SpA in clinical practice
Pulmonary hypertension: reasonable selection of specific therapy
Pulmonary hypertension is characterized with persistent increase in pulmonary vascular resistance leading to progressive worsening of right ventricular failure and death. The basis for pulmonary arterial hypertension is structural changes in pulmonary arteries and arterioles caused by endothelial dysfunction. Endothelin-1 is the main pathogenic trigger of pulmonary hypertension and potential target for therapeutic exposure. The efficacy of endothelin receptor antagonists is proved in various preclinical and clinical studies. In patients with pulmonary arterial hypertension, the efficacy of dual and selective endothelin receptor antagonists is comparable despite the varied activity against various receptors. Bosentan is the most widely used pulmonary vasodilator which improves exercise tolerance and decelerates disease progression
Mechanistic Insights into the Desorption of Methanol and Dimethyl Ether Over ZSM-5 Catalysts
Acknowledgements Financial support from the Petroleum Technology Development Fund of Nigeria (PTDF/ED/PHD/OO/766/15) and from the European Commission in the scope of the 7th Framework program BIOGO project (Grant Number: 604296) https://www.biogo. eu/ is acknowledged.Peer reviewedPublisher PD
ΠΡΠ²Π΅Ρ Π½Π° Β«ΠΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΊ ΡΡΠ°ΡΡΠ΅ βΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°: Π½ΡΠΆΠ½Ρ Π»ΠΈ Π½Π°ΠΌ Π½ΠΎΠ²ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ?βΒ», ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΠ΅ Π² ΠΆΡΡΠ½Π°Π»Π΅ Β«Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΒ»
Π ΠΏΠ΅ΡΠ²ΠΎΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Β«Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΒ» Π·Π° 2015 Π³. Π±ΡΠ»Π° ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π° ΡΡΠ°ΡΡΡ Π.Π. ΠΠ°ΠΉΠ΄ΡΠΊΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΊΡΠ»ΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΏΠ°ΡΠΊΠΈΠ½ΠΎΠΉ, Π.Π. Π Π΅Π±ΡΠΎΠ²Π° Β«ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°: Π½ΡΠΆΠ½Ρ Π»ΠΈ Π½Π°ΠΌ Π½ΠΎΠ²ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ?Β». Π ΠΎΡΠ²Π΅Ρ Π½Π° ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΡ ΡΡΠ°ΡΡΠΈ Π² ΡΡΠ΅ΡΡΠ΅ΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Π²ΡΡΠ»ΠΈ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΡΠ° Π¨.Π€. ΠΡΠ΄Π΅ΡΠ°.Π ΠΏΠ΅ΡΠ²ΠΎΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Β«Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΒ» Π·Π° 2015 Π³. Π±ΡΠ»Π° ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π° ΡΡΠ°ΡΡΡ Π.Π. ΠΠ°ΠΉΠ΄ΡΠΊΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΊΡΠ»ΠΎΠ²ΠΎΠΉ, Π.Π. ΠΠΏΠ°ΡΠΊΠΈΠ½ΠΎΠΉ, Π.Π. Π Π΅Π±ΡΠΎΠ²Π° Β«ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°: Π½ΡΠΆΠ½Ρ Π»ΠΈ Π½Π°ΠΌ Π½ΠΎΠ²ΡΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ?Β». Π ΠΎΡΠ²Π΅Ρ Π½Π° ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΡ ΡΡΠ°ΡΡΠΈ Π² ΡΡΠ΅ΡΡΠ΅ΠΌ Π½ΠΎΠΌΠ΅ΡΠ΅ ΠΆΡΡΠ½Π°Π»Π° Π²ΡΡΠ»ΠΈ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΡΠ° Π¨.Π€. ΠΡΠ΄Π΅ΡΠ°
Non-Equilibrium Reaction Rates in the Macroscopic Chemistry Method for DSMC Calculations
The Direct Simulation Monte Carlo (DSMC) method is used to simulate the flow of rarefied gases. In the Macroscopic Chemistry Method (MCM) for DSMC, chemical reaction rates calculated from local macroscopic flow properties are enforced in each cell. Unlike the standard total collision energy (TCE) chemistry model for DSMC, the new method is not restricted to an Arrhenius form of the reaction rate coefficient, nor is it restricted to a collision cross-section which yields a simple power-law viscosity. For reaction rates of interest in aerospace applications, chemically reacting collisions are generally infrequent events and, as such, local equilibrium conditions are established before a significant number of chemical reactions occur. Hence, the reaction rates which have been used in MCM have been calculated from the reaction rate data which are expected to be correct only for conditions of thermal equilibrium. Here we consider artificially high reaction rates so that the fraction of reacting collisions is not small and propose a simple method of estimating the rates of chemical reactions which can be used in the Macroscopic Chemistry Method in both equilibrium and non-equilibrium conditions. Two tests are presented: (1) The dissociation rates under conditions of thermal non-equilibrium are determined from a zero-dimensional Monte-Carlo sampling procedure which simulates βintra-modalβ non-equilibrium; that is, equilibrium distributions in each of the translational, rotational and vibrational modes but with different temperatures for each mode; (2) The 2-D hypersonic flow of molecular oxygen over a vertical plate at Mach 30 is calculated. In both cases the new method produces results in close agreement with those given by the standard TCE model in the same highly nonequilibrium conditions. We conclude that the general method of estimating the non-equilibrium reaction rate is a simple means by which information contained within non-equilibrium distribution functions predicted by the DSMC method can be included in the Macroscopic Chemistry Method
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ½Π° ΠΈ Ρ ΠΎΠ½Π΄ΡΠΎΠΈΡΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π³ΠΎΠ½Π°ΡΡΡΠΎΠ·ΠΎΠΌ, Π½Π΅ ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΠΈΡ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ
Objective: to evaluate the efficacy and tolerability of the combined symptomatic slow-acting combined agent Theraflex in gonarthrosis patients untreated with nonsteroidal antiinflammatory drugs (NSAIDs).Patients and methods. The investigation enrolled 84 patients (78 women and 6 men) aged 55.23Β±7.36 years with knee arthritis lasting 6.2Β±0.98 years who were blindly randomized into 2 groups. A study group took Theraflex (chondroitin sulfate 400 mg and glucosamine sulfate 500 mg) with or without acetaminophen. A comparison group received acetaminophen only. At baseline and 3 and 6 months after treatment, the investigators assessed changes in the magnitude of osteoarthritis (OA) using WOMAC and Lequen's indices, evaluated the therapeutic efficiency rated by a patient and a physician according to the visual analogue scale, and took into account adverse reactions (AR).Results. All the patients taking Theraflex for 6 months showed a positive effect in substantially lowering WOMAC and Lequen's indices and reducing pain and needs for analgesics as compared to both the values at baseline and those obtained in the patients receiving acetaminophen only.Conclusion. In osteoarthritis patients untreated with NSAIDs, Theraflex treatment was associated with a reduction in pain syndrome and stiffness and with better function and lower needs for analgesics. Six-month Theraflex therapy did not cause serious ARs, as well as in patients having controlled gastrointestinal and renal diseases and hypertensionΠ¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠΌΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π·Π°ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³ΠΎΠ½Π°ΡΡΡΠΎΠ·ΠΎΠΌ, Π½Π΅ ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΠΈΡ
Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ (ΠΠΠΠ).ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 84 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π°ΡΡΡΠΎΠ·ΠΎΠΌ ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΡΡΠ°Π²Π° (Π²ΠΎΠ·ΡΠ°ΡΡ 55,23Β±7,36 Π³ΠΎΠ΄Π°, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ β 6,2Β±0,98 Π³ΠΎΠ΄Π°, ΠΆΠ΅Π½ΡΠΈΠ½Ρ/ΠΌΡΠΆΡΠΈΠ½Ρ β 78/6), ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π²ΡΠ»Π΅ΠΏΡΡ Π² Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ (400 ΠΌΠ³ Ρ
ΠΎΠ½Π΄ΡΠΎΠΈΡΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ° ΠΈ 500 ΠΌΠ³ Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ°) Ρ/Π±Π΅Π· Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½Π°, ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ β ΡΠΎΠ»ΡΠΊΠΎ Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½. ΠΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 3 ΠΈ 6 ΠΌΠ΅Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΎΡΡΠ΅ΠΎΠ°ΡΡΡΠΎΠ·Π° (ΠΠ) Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² WOMAC, ΠΠ΅ΠΊΠ΅Π½Π°, ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΎΡΠ΅Π½ΠΊΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΡΠ°ΡΠΎΠΌ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΌ ΠΏΠΎ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΠΎΠΉ Π°Π½Π°Π»ΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π»Π΅, ΡΡΠΈΡΡΠ²Π°Π»ΠΈ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ ).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π²ΡΠΈΡ
ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ 6 ΠΌΠ΅Ρ, ΠΎΡΠΌΠ΅ΡΠ΅Π½ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ, Π²ΡΡΠ°Π·ΠΈΠ²ΡΠΈΠΉΡΡ Π² ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² WOMAC, ΠΠ΅ΠΊΠ΅Π½Π°, ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΈ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΠΈ Π² Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠ°Ρ
ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΊΠ°ΠΊ Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ, ΡΠ°ΠΊ ΠΈ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠΎΠ»ΡΠΊΠΎ Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½. Π‘Π΄Π΅Π»Π°Π½ Π²ΡΠ²ΠΎΠ΄, ΡΡΠΎ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ, Π½Π΅ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΠΠΠ, Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡΠΎΠΌ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π»ΠΎΡΡ Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°, ΡΠΊΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ ΠΈ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΠΈ Π² ΠΏΡΠΈΠ΅ΠΌΠ΅ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠΎΠ². ΠΠ° ΡΠΎΠ½Π΅ 6-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡΠ° Π½Π΅ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΠ΅ΡΡΠ΅Π·Π½ΡΡ
ΠΠ , Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠΌΠ΅Π²ΡΠΈΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎ-ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°, ΠΏΠΎΡΠ΅ΠΊ ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ
ΠΠ°ΡΠ΄ΠΈΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½Π°Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ Ρ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ½Π° ΠΈ Ρ ΠΎΠ½Π΄ΡΠΎΠΈΡΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ°1 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π³ΠΎΠ½Π°ΡΡΡΠΎΠ·ΠΎΠΌ
Objective: to investigate the clinical efficacy and cardiovascular safety of the combined symptomatic slow-acting drug glucosamine and chondroitinΒ sulfate in patients with osteoarthritis (OA) and hypertension.Subjects and methods. The investigation enrolled 44 patients (a female:male ratio of 40:4) aged 54.5Β±7.4 years with knee OA (duration,Β 6.4Β±1.54 years). The patients were blindly randomized into two groups: 1) those who received antihypertensive therapy, teraflex (chondroitinΒ sulfate 400 mg and glucosamine sulfate 500 mg) with/without acetaminophen; 2) those who had antihypertensive therapy and acetaminophen.Β At baseline and 3 and 6 months after treatment, the investigators assessed a change in the degree of OA by the WOMAC and Lequesne indices,Β the treatment efficiency evaluated by a physician and a patient using a visual analogue scale, and cardiovascular safety (during the first andΒ last visits) through examination of the antithrombogenic properties of the vascular wall and arterial stiffness.Results. All the patients taking teraflex for 6 months were observed to have a positive effect manifesting as a substantial reduction in WOMACΒ and Lequesne indices, pain syndrome, and needs for analgesics compared to both the baseline level and parameters in the patients receivingΒ acetaminophen only. Teraflex therapy showed an increase in the fibrinolytic activity of the vascular wall. A more obvious fall in augmentationΒ index and pulse wave velocity was seen in OA and AG patients receiving antihypertensive therapy and teraflex.Conclusion. Group 1 displayed not only reductions in pain syndrome and needs for analgesics, but also no blood pressure destabilization. TheyΒ also had lower endothelial dysfunction manifesting as enhanced fibrinolytic activity of the vascular wall, decreased brachial and aortic augmentationΒ indices, and lower pulse wave velocity.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΡΡΠ΅Π³ΠΎ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ½Π° ΠΈ Ρ
ΠΎΠ½Π΄ΡΠΎΠΈΡΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΠ΅ΠΎΠ°ΡΡΡΠΈΡΠΎΠΌ (ΠΠ) ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ (ΠΠ).ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 44 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΠ ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΡΡΠ°Π²Π° (Π²ΠΎΠ·ΡΠ°ΡΡ β 54,5Β±7,4 Π³ΠΎΠ΄Π°, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΒ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ β 6,4Β±1,54 Π³ΠΎΠ΄Π°, ΠΆΠ΅Π½ΡΠΈΠ½Ρ/ΠΌΡΠΆΡΠΈΠ½Ρ β 40/4). ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π²ΡΠ»Π΅ΠΏΡΡ Π² Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ: ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ 1-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ (400 ΠΌΠ³ Ρ
ΠΎΠ½Π΄ΡΠΎΠΈΡΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ° ΠΈ 500 ΠΌΠ³ Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ½Π° ΡΡΠ»ΡΡΠ°ΡΠ°) Ρ (Π±Π΅Π·)Β Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½Π°; ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ 2-ΠΉ Π³ΡΡΠΏΠΏΡ β Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈ Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½. ΠΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 3 ΠΈ 6 ΠΌΠ΅Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΠ ΠΏΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ°ΠΌ WOMAC, ΠΠ΅ΠΊΠ΅Π½Π°, ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΡΠ°ΡΠΎΠΌ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΌ ΠΏΠΎ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΠΎΠΉΒ Π°Π½Π°Π»ΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π»Π΅, ΠΊΠ°ΡΠ΄ΠΈΠΎΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ (Π²ΠΎ Π²ΡΠ΅ΠΌΡ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΈ Π·Π°ΠΊΠ»ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΈΠ·ΠΈΡΠΎΠ²) Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π°Π½ΡΠΈΡΡΠΎΠΌΠ±ΠΎΠ³Π΅Π½Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ ΠΈ ΠΆΠ΅ΡΡΠΊΠΎΡΡΠΈ Π°ΡΡΠ΅ΡΠΈΠΉ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π²ΡΠΈΡ
ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ 6 ΠΌΠ΅Ρ, ΠΎΡΠΌΠ΅ΡΠ΅Π½ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ, Π²ΡΡΠ°Π·ΠΈΠ²ΡΠΈΠΉΡΡΒ Π² ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² WOMAC, ΠΠ΅ΠΊΠ΅Π½Π°, ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΈ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΠΈ Π² Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠ°Ρ
ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡΒ ΠΊΠ°ΠΊ Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ, ΡΠ°ΠΊ ΠΈ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠΎΠ»ΡΠΊΠΎ Π°ΡΠ΅ΡΠ°ΠΌΠΈΠ½ΠΎΡΠ΅Π½. ΠΡΡΠ²Π»Π΅Π½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡΠΎΠΌ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ ΠΈ ΠΠ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈ ΡΠ΅ΡΠ°ΡΠ»Π΅ΠΊΡ, Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΠ° Π°ΡΠ³ΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΈ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΏΡΠ»ΡΡΠΎΠ²ΠΎΠΉ Π²ΠΎΠ»Π½Ρ.ΠΡΠ²ΠΎΠ΄Ρ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ Π³ΡΡΠΏΠΏΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΠΌΠ΅Π½ΡΡΠ°Π»ΠΈΡΡ Π±ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΈ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΡ Π² ΠΏΡΠΈΠ΅ΠΌΠ΅ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠΎΠ², Π½ΠΎ ΠΈ Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΠΠ. ΠΠ°Π±Π»ΡΠ΄Π°Π»ΠΈΡΡ ΡΠ°ΠΊΠΆΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ, Π²ΡΡΠ°ΠΆΠ°Π²ΡΠ΅Π΅ΡΡ Π² ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠΈ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π±ΡΠ°Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ Π°ΠΎΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² Π°ΡΠ³ΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ, ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΏΡΠ»ΡΡΠΎΠ²ΠΎΠΉ Π²ΠΎΠ»Π½Ρ
Π Π΅ΠΌΠΈΡΡΠΈΡ ΠΏΡΠΈ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠ΅ΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠ΅ ΠΈ Π°ΠΊΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°Ρ : ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ
The paper discusses possible approaches to determining remission in ankylosing spondylitis (AS) and other axial spondyloarthritides (axSpA). At present, there is no single definition of the concept of remission in axSpA and AS, which is due to both the diversity of manifestations of axSpA and a large number of tools to measure disease activity and the nonsimultaneous change in the degree of clinical and laboratory symptoms, signs of acute inflammation, as evidenced by imaging techniques, and signs of progressive structural changes in the locomotor apparatus in the same patient. Clinical, laboratory, magnetic resonance imaging, and radiographic remissions in a patient cannot be in time, which in turn affects the choice of optimal therapy.The case report demonstrates problems with treatment correction in a patient who has achieved clinical and laboratory remission in the presence of persistent inflammatory signs in the locomotor apparatus, as shown by imaging techniques. Since the guidelines for the follow-up and treatment of patients with nonradiographic axSpA and AS are similar today, the paper considers remission as a general problem for all subtypes of axSpA.ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΏΡΠΈ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠ΅ΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠ΅ (ΠΠ‘) ΠΈ Π΄ΡΡΠ³ΠΈΡ
Π°ΠΊΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°Ρ
(Π°ΠΊΡΠ‘ΠΏΠ).Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ½ΡΡΠΈΡ Β«ΡΠ΅ΠΌΠΈΡΡΠΈΡΒ» ΠΏΡΠΈ Π°ΠΊΡΠ‘ΠΏΠ ΠΈ ΠΠ‘ Π½Π΅ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ, ΡΡΠΎ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½ΠΎ ΠΊΠ°ΠΊ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ΠΌ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π°ΠΊΡΠ‘ΠΏΠ ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠΈΡΠ»Π° ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠ² ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ°ΠΊ ΠΈ Π½Π΅ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ², ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΎΡΡΡΠΎΠ³ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·ΠΈΡΡΡΡΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΈ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΎΠΏΠΎΡΠ½ΠΎ-Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ° Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈ ΡΠΎΠ³ΠΎ ΠΆΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π£ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠΆΠ΅Ρ Π½Π΅ ΡΠΎΠ²ΠΏΠ°Π΄Π°ΡΡ ΠΏΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½Π°Ρ, ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎ-ΡΠ΅Π·ΠΎΠ½Π°Π½ΡΠ½Π°Ρ ΠΈ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΠΌΠΈΡΡΠΈΡ, ΡΡΠΎ Π² ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ Π²Π»ΠΈΡΠ΅Ρ Π½Π° Π²ΡΠ±ΠΎΡ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.ΠΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, Π΄ΠΎΡΡΠΈΠ³ΡΠ΅Π³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΏΡΠΈ ΡΠΎΡ
ΡΠ°Π½ΡΡΡΠΈΡ
ΡΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΡΡ
Π² ΠΎΠΏΠΎΡΠ½ΠΎ-Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠΌ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ΅ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·ΠΈΡΡΡΡΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ². Π’Π°ΠΊ ΠΊΠ°ΠΊ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π½Π΅ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΠΊΡΠ‘ΠΏΠ ΠΈ ΠΠ‘ ΡΠ΅Π³ΠΎΠ΄Π½Ρ Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°ΡΡΡΡ, Π² ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ Π΅Π΄ΠΈΠ½Π°Ρ Π΄Π»Ρ Π²ΡΠ΅Ρ
ΠΏΠΎΠ΄ΡΠΈΠΏΠΎΠ² Π°ΠΊΡΠ‘ΠΏΠ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ
ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠΎΠ²: ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠΎΠ΄Π°Π²Π°Π½ΠΈΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ ΡΠΌΠ΅Π½Ρ ΠΏΠ°ΡΠ°Π΄ΠΈΠ³ΠΌΡ Π² ΠΎΡΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π·Π½Π°Π½ΠΈΠΉ
Objective: to show the characteristics of teaching this area of clinical medicine in the context of new knowledge and to identify ways of introducing new data into teaching practice by the example of development of the concept of spondyloarthritis (SpA). Material and methods. At Stage 1, by using the keywords: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, rehabilitation care, and Bechterew's disease, the articles published in January 1951 to January 2017 were sought in the electronic resources PubMed, MedLine, and e-library. The fundamental aspects of the pathogenesis, diagnosis, and treatment of SpA, which need to be introduced into a pedagogical process, were assessed. At Stage 2, by using the analyzed data, the authors proposed to optimize the teaching of the SpA concept in the clinical presentations of visceral diseases. Results. Analysis of the data available in the literature could determine the key points of the new concept of SpA and the ways of its introduction into teaching practice at medical universities and during postgraduate training of physicians.Β Π¦Π΅Π»Ρ ΡΡΠ°ΡΡΠΈ β Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠΎΠ² (Π‘ΠΏΠ) ΠΏΠΎΠΊΠ°Π·Π°ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠΎΠ΄Π°Π²Π°Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΡΠ°Π·Π΄Π΅Π»Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π½ΠΎΠ²ΡΡ
Π·Π½Π°Π½ΠΈΠΉ ΠΈ Π½Π°ΠΌΠ΅ΡΠΈΡΡ ΠΏΡΡΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ Π½ΠΎΠ²ΡΡ
Π΄Π°Π½Π½ΡΡ
Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΡΠ΅ΠΏΠΎΠ΄Π°Π²Π°Π½ΠΈΡ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ° ΠΏΠ΅ΡΠ²ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΡ
ΡΠ΅ΡΡΡΡΠΎΠ² PubMed, MedLine, e-library Π²ΡΠΏΠΎΠ»Π½Π΅Π½ ΠΏΠΎΠΈΡΠΊ ΡΡΠ°ΡΠ΅ΠΉ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΡΠ΅ΠΌΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΡΠ½Π²Π°ΡΡ 1951 Π³. ΠΏΠΎ ΡΠ½Π²Π°ΡΡ 2017 Π³., ΠΏΠΎ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌ ΡΠ»ΠΎΠ²Π°ΠΌ: ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΡ, Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΉ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ, ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ, ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΠΏΠΎΠΌΠΎΡΡ, Π±ΠΎΠ»Π΅Π·Π½Ρ ΠΠ΅Ρ
ΡΠ΅ΡΠ΅Π²Π°. ΠΡΠ΅Π½Π΅Π½Ρ ΠΎΡΠ½ΠΎΠ²ΠΎΠΏΠΎΠ»Π°Π³Π°ΡΡΠΈΠ΅ ΠΌΠΎΠΌΠ΅Π½ΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π°, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, Π»Π΅ΡΠ΅Π½ΠΈΡ Π‘ΠΏΠ, Π½ΡΠΆΠ΄Π°ΡΡΠΈΠ΅ΡΡ Π²ΠΎ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠΈ Π² ΠΏΠ΅Π΄Π°Π³ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ. ΠΠ° Π²ΡΠΎΡΠΎΠΌ ΡΡΠ°ΠΏΠ΅ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΈΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ ΠΎΠΏΡΠΈΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΠΏΡΠ΅ΠΏΠΎΠ΄Π°Π²Π°Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ Π‘ΠΏΠ Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΠΈ Π‘ΠΏΠ ΠΈ ΠΏΡΡΠΈ Π΅Π΅ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΡΠ΅ΠΏΠΎΠ΄Π°Π²Π°Π½ΠΈΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π²ΡΠ·Π°Ρ
ΠΈ Π½Π° ΡΡΠ°ΠΏΠ΅ ΠΏΠΎΡΠ»Π΅Π΄ΠΈΠΏΠ»ΠΎΠΌΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠ°ΡΠ΅ΠΉ.
- β¦